The Role of Biosimilars in Cancer Treatment
Challenges remain in the acceptance of biosimilars by physicians, payers and patients in the U.S., similar to those faced by generic drugs when they were first introduced to the market. Increased education and awareness of the FDA-approval process for biosimilars and increased understanding of the evidence required to demonstrate their safety and efficacy will help to close this practice gap and ensure the acceptance and use of biosimilars in clinical practice.
  • Biosimilars
  • Enduring Activity
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation